Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial.
Johnny LudvigssonIndusmita RoutraySriramulu ElluruPer LeandersonHelena Elding LarssonBjörn RathsmanRagnar HanasAnnelie CarlssonTorben EkUlf SamuelssonTorun TorbjörnsdotterJan ÅmanEva ÖrtqvistKarun BadwalCraig A BeamRosaura CasasPublished in: Future science OA (2020)
Ibuprofen, vitamin D + GAD-alum did not preserve C-peptide. Treatment efficacy was influenced by baseline clinical and immunological factors and vitamin D concentration. Clinical Trial Registration: NCT01785108 (ClinicalTrials.gov).